A tiny blood vessel that normally closes soon after birth is once again at the center of a major debate in neonatal medicine. In a 2026 article published in Pediatric Research, G.M. Schmölzer revisits the question of how clinicians should approach patent ductus arteriosus, or PDA, a persistent connection between two major arteries in newborns. The title—“Patent ductus arteriosus: Are we finally asking the right question?”—signals a shift in focus. Instead of asking only whether the vessel is open, the field is increasingly asking whether it is causing harm, which infants are most vulnerable, and whether treatment improves meaningful outcomes.
The ductus arteriosus is a normal fetal structure that connects the pulmonary artery to the aorta. Before birth, the fetus does not use the lungs for oxygen exchange; oxygen-rich blood arrives through the placenta, and the ductus helps divert blood away from the fluid-filled lungs. After delivery, the lungs expand, oxygen levels rise, and placental circulation stops. These changes usually trigger functional closure of the ductus, followed by permanent anatomical sealing. In some premature infants, however, the vessel remains open. This condition, known as PDA, can allow blood to flow continuously from the higher-pressure aorta into the pulmonary arteries, creating what physicians call a left-to-right shunt.
That shunt can place stress on an immature cardiovascular system. Excess blood may be pushed toward the lungs, increasing pulmonary blood flow and potentially interfering with ventilation. At the same time, the circulation supplying organs such as the kidneys, intestines, and brain may receive less effective blood flow, particularly when the ductus is large and the infant’s ability to compensate is limited. The consequences can include respiratory deterioration, difficulty reducing ventilator support, pulmonary edema, impaired kidney function, and intestinal complications. Yet the presence of an open ductus does not automatically mean that these problems will occur. Many infants have a PDA that is small, transient, or clinically insignificant.
That distinction has made PDA one of the most contested issues in neonatal care. For decades, clinicians often treated an echocardiographically visible ductus with medications designed to promote closure, including indomethacin, ibuprofen, and, in some settings, acetaminophen. Surgical ligation or catheter-based closure may be considered when a PDA is large, persistent, and associated with serious cardiovascular effects. The underlying logic appears straightforward: if the ductus can impose an abnormal workload on the heart and lungs, closing it should improve the infant’s condition. But neonatal physiology is rarely that simple, and clinical trials have not consistently shown that routine closure translates into better long-term outcomes.
The central problem is that PDA is not a single condition with a uniform biological effect. Its impact depends on the diameter and shape of the ductus, the amount of blood crossing it, the pressure in the pulmonary circulation, the infant’s gestational age, lung disease, cardiac function, fluid status, and the ability of other vessels to regulate blood flow. Echocardiography can reveal whether the ductus is open and can provide clues about shunt volume, but measurements such as ductal diameter or flow pattern do not always predict how an individual infant will respond. A vessel that appears substantial on an ultrasound may be tolerated in one patient but destabilizing in another.
This uncertainty has challenged the idea that anatomical closure should be the primary goal. Drug treatment is not harmless: cyclooxygenase inhibitors can reduce blood flow to the kidneys and intestines, affect platelet function, and create complications in infants who are already medically fragile. Acetaminophen may have a different safety profile, but it also requires careful consideration of liver function, dose, timing, and long-term evidence. Invasive procedures carry their own risks, including bleeding, infection, vocal-cord injury after surgical ligation, and complications associated with catheter access. The crucial question, therefore, is not simply whether clinicians can close a PDA, but whether closing it at a particular moment will produce a net benefit greater than the risks of intervention.
Schmölzer’s article arrives as neonatal researchers increasingly distinguish between a “hemodynamically significant” PDA and an incidental finding. The term refers to a ductus that produces measurable cardiovascular consequences, rather than merely remaining anatomically open. Clinicians may look for signs such as left-heart enlargement, excessive pulmonary blood flow, reduced systemic perfusion, changes in diastolic blood flow, worsening respiratory status, or an inability to progress with feeding and other supportive care. Even these indicators must be interpreted in context. A premature infant with severe lung disease may deteriorate for several reasons at once, making it difficult to identify the ductus as the true driver of illness.
The most important shift may be toward individualized, physiology-based management. Instead of automatically treating every open ductus or waiting indefinitely for spontaneous closure, physicians could combine serial echocardiography with bedside signs of organ perfusion and respiratory performance. This approach recognizes that the ductus can change rapidly as pulmonary resistance falls, fluids are adjusted, infection develops, or respiratory support is modified. A watchful strategy may be reasonable for an infant who is stable and showing no evidence of excessive shunting, while targeted treatment could be more compelling when the ductus is large, persistent, and linked to cardiovascular compromise. The challenge is converting this concept into reliable criteria that can be applied across hospitals and populations.
The debate also reflects a broader lesson in medicine: correcting an abnormal test result is not the same as improving a patient’s future. Neonatal outcomes such as survival without bronchopulmonary dysplasia, severe brain injury, intestinal disease, or long-term neurodevelopmental impairment matter more than ductal closure alone. Future research will need to determine which combinations of echocardiographic measurements, clinical findings, biomarkers, and timing can identify infants most likely to benefit from intervention. It will also need to clarify whether early treatment, delayed treatment, or conservative care produces the best balance of benefit and harm for distinct groups of premature newborns.
The question raised by this 2026 Pediatric Research article is therefore larger than the fate of one fetal blood vessel. It asks whether neonatal medicine is ready to move beyond a binary definition of PDA—open or closed—and toward a more precise understanding of circulation, organ vulnerability, and treatment response. For parents and clinicians confronting a fragile newborn’s diagnosis, that distinction is critical. An open ductus may be a dangerous source of cardiovascular strain, a temporary feature of prematurity, or something in between. The next generation of PDA care will depend on identifying which infant is in which category, and on proving that the chosen intervention changes the outcomes that matter long after the ultrasound image has disappeared.
Subject of Research: Patent ductus arteriosus in newborns, particularly its diagnosis, clinical significance, and treatment in premature infants.
Article Title: Patent ductus arteriosus: Are we finally asking the right question?
Article References: Schmölzer, G.M. “Patent ductus arteriosus: Are we finally asking the right question?” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05415-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41390-026-05415-4
Keywords: Patent ductus arteriosus, PDA, premature infants, neonatal medicine, preterm birth, echocardiography, cardiovascular physiology, neonatal treatment, pulmonary blood flow, intensive care.
